Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates

Los Angeles, California, UNITED STATES

LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of the first FDA-approved treatment for lactose intolerance, today reported financial results for the first quarter ended March 31, 2018 and provided other business updates.

Recent Highlights

  • Engaged Medpace as the Company’s clinical research organization (CRO) for its first pivotal Phase 3 clinical trial of RP-G28 in lactose intolerance.
  • Reported clinical microbiome data from the Company’s Phase 2b clinical trial of RP-G28 indicating that RP-G28 promoted beneficial adaptation of the gut microbiome.
  • Completed 1-for-10 reverse stock split.
  • Conducted a Phase 1 clinical pharmacology study of RP-G28 to support the Company’s planned Phase 3 program.
  • Welcomed William Chey, M.D. to the Company’s Medical Advisory Board.
  • Appointed Diane J. Plotkin, Ph.D. as Vice President of Clinical Development.

“We began 2018 with several important corporate and product development updates, each with significant impact on our strategic execution of our first Phase 3 pivotal trial,” said Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals. “Our efforts have centered around finalizing the Phase 3 trial protocol design based on the Food and Drug Administration’s feedback and guidance, completion of manufacturing of drug supply and securing additional late-stage clinical development personnel to assist us in the execution of the program.”

Andrew J. Ritter, co-founder and President of Ritter Pharmaceuticals, added, “ We continue to be committed to ensuring that the clinical development of RP-G28 is executed safely and with scientific rigor, and we look forward to initiating our first pivotal Phase 3 Trial later this quarter.”

First Quarter 2018 Financial Results
For the first quarter of 2018, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $2.0 million compared to a net loss of approximately $1.7 million for the first quarter of 2017. Basic and diluted net loss per share was $0.41 for the three months ended March 31, 2018 compared to basic and diluted net loss per share of $1.44 for the same period in 2017. Research and development expenses for the first quarter of 2018 totaled approximately $850,000 compared to approximately $432,000 for the first quarter of 2017. This increase was due to the Company’s preparation for its Phase 3 clinical trial. General and administrative expenses for the first quarter of 2018 and 2017 were approximately $1.1 million and $1.2 million, respectively. As of March 31, 2018, Ritter Pharmaceuticals had cash and cash equivalents of approximately $18.9 million.

About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The Company’s lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions of people worldwide. RP-G28 has been studied in Phase 2 trials, and is expected to commence Phase 3 clinical development in the second quarter of 2018. The Company is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including: gastrointestinal diseases, cancer, metabolic, and liver disease.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of Ritter Pharmaceuticals’ management, including statements regarding the timing and commencement of our first Phase 3 clinical trial. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

Shaun Novin

  For the Three Months Ended March 31,
     2018    2017
Operating costs and expenses      
Research and development $849,683  $432,154 
Patent costs  63,088   77,702 
General and administrative  1,125,891   1,171,325 
Total operating costs and expenses  2,038,662   1,681,181 
Operating loss  (2,038,662)  (1,681,181)
Other income      
Interest income  25,972   7,946 
Total other income  25,972   7,946 
Net loss $(2,012,690) $(1,673,235)
Net loss per common share - basic and diluted $(0.41) $(1.44)
Weighted average common shares outstanding - basic and diluted  4,944,763   1,161,920 

  March 31, 2018 December 31, 2017
Current assets      
Cash and cash equivalents $18,917,043  $22,631,971 
Prepaid expenses  177,085   167,400 
Total current assets $19,094,128  $22,799,371 
Other assets  10,326   10,326 
Property and equipment, net  22,510   23,873 
Total Assets $19,126,964  $22,833,570 
Current liabilities      
Accounts payable $640,545  $2,237,579 
Accrued expenses  145,216   454,252 
Other liabilities  15,303   15,757 
Total current liabilities  801,064   2,707,588 
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 8,820
and 9,140 shares issued and outstanding as of March 31, 2018 and
December 31, 2017, respectively
  4,948,981   5,128,536 
Common stock, $0.001 par value; 225,000,000 shares authorized,
5,020,652 and 4,940,652 shares issued and outstanding as of March 31,
2018 and December 31, 2017, respectively
  5,021   4,941 
Additional paid-in capital  68,716,022   68,323,939 
Accumulated deficit  (55,344,124)  (53,331,434)
Total stockholders’ equity  18,325,900   20,125,982 
Total Liabilities and Stockholders’ Equity $19,126,964  $22,833,570